Surgical Safety of Deferred Cytoreductive Nephrectomy Following Pretreatment with Immune Checkpoint Inhibitor–based Dual Combination Therapy
Authors:
- 1 June 2022
- journal article
- letter
- Published by Elsevier in European Urology Oncology
- Vol. 5 (3) , 373-374
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell CarcinomaEuropean Urology Oncology, 2020
- Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?European Urology, 2020
- Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2019
- Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell CarcinomaEuropean Urology, 2019
- Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).Journal of Clinical Oncology, 2019